OBJECTIVE: This randomized, doubleblind study investigated the suitable target effect-site concentration of remifentanil for laryngeal mask airway (LMA) insertion during inhalation induction with sevoflurane. METHODS: Patients aged 18 -60 years were randomly assigned to one of three groups receiving infusions of normal saline (control group), or infusions with target effect-site remifentanil concentrations of either 1 ng/ml (R1 group) or 2 ng/ml (R2 group), 1 min after the induction of anaesthesia with sevoflurane. LMA insertion was attempted 2 min after induction. Insertion conditions were graded using a six-variable, three-point scale (excellent, intermediate or poor). RESULTS: A total of 102 patients were included. The proportion of patients ranked as excellent for the LMA insertion was significantly higher in groups R1 and R2 compared with the control group. The incidence of apnoea was significantly more frequent in the R2 group than in the control or R1 groups. CONCLUSIONS: Compared with 1 ng/ml remifentanil or normal saline, target-controlled infusion of 2 ng/ml remifentanil significantly improved the LMA insertion conditions during sevoflurane inhalational induction, although apnoeic episodes were more frequently observed.
Introduction
Sevoflurane is considered to be the volatile anaesthetic of choice for LMA insertion. 1,2 It has been shown to provide better haemodynamic stability and a smoother transition to the maintenance phase, without a period of apnoea, compared with anaesthetic induction with propofol. 3 -5 Inhalation induction with sevoflurane alone is often associated with a higher incidence of excitatory movements during induction and a prolonged time to jaw relaxation, compared with inhalation induction with propofol. 6, 7 Opioids are often used to facilitate insertion of the LMA during anaesthesia induction as they can suppress upper airway reflexes. 8 -11 Remifentanil has favourable pharmaco kinetic properties with rapid onset and offset of action, which make it an appropriate adjunct to sevoflurane induction. There have, however, been no specific studies assessing the use of HJ Kwak, YJ Chae, KC Lee et al. LMA insertion with sevoflurane and remifentanil remifentanil to facilitate LMA insertion during sevoflurane inhalation induction in adult patients.
The present study evaluated the suitable target effect-site concentration of remifentanil for LMA insertion in adult patients, during tidal volume breathing inhalation induction with 8% sevoflurane.
Patients and methods

STUDY POPULATION
Patients scheduled for short elective surgery at Ajou University Hospital, Suwon, Republic of Korea, aged between 18 and 60 years, with American Society of Anesthesiologists physical status I or II, 12 were eligible to be enrolled in this study, which took place between April and December 2011. Patients were randomly assigned, according to a computer-generated randomization table, to one of three groups: control group (infusion of normal saline); R1 group (infusion with a target effect-site remifentanil concentration of 1 ng/ml); R2 group (infusion with a target effect-site remifentanil concentration of 2 ng/ml). Patients were blinded to the treatment assignment; study drugs were prepared by an independent researcher not involved with patient anaesthetic care. A researcher blinded to the study group recorded the insertion condition score for each patient. Patients with allergies to any of the study drugs, a history of gastric reflux, a suspected difficult airway, history of drug abuse or a body mass index > 30 kg/m 2 were excluded from this study.
The study protocol was approved by the Institutional Review Board of Ajou University Hospital. All patients provided written informed consent prior to study entry.
ANAESTHESIA AND LMA INSERTION
Patients were not premedicated before surgery. For all patients, anaesthesia was induced via a facemask with 8% sevoflurane mixed in 100% oxygen, at a total gas flow rate of 6 l/min. At 1 min after induction, the predetermined target effect-site concentration of remifentanil or normal saline was administered according to the patient's group assignment, using a target controlled infusion (TCI) pump (Orchestra ® ; Fresenius Vial, Brézins, France). The remifentanil concentration was maintained according to the pharmacokinetic model of Minto et al. 13 At 2 min after induction, all patients underwent insertion of an LMA (LMA Classic™; The Laryngeal Mask Airway Co., Nicosia, Cyprus). LMA insertion was performed according to the manufacturer's recommendations 14 by one experienced anaesthesiologist who was blinded to each patient's group assignment. The LMA sizes used were size 3 for patients with body weight 40 -70 kg and size 4 for patients with body weight 70 -90 kg.
Insertion conditions were graded on a three-point scale using six variables (mouth opening, ease of LMA insertion, swallowing, coughing and gagging, head or body movement, laryngospasm). 15 Each variable was rated as excellent, intermediate or poor. Insertion conditions were rated as excellent if all criteria were scored as excellent, intermediate if all criteria were scored as either excellent or intermediate and poor if a single criterion was scored as poor. If the first LMA insertion attempt failed, a second attempt was made after 1 min of facemask ventilation. If laryngospasm developed or the second attempt failed, 0.3 mg/kg rocuronium was administered intravenously, to achieve neuromuscular relaxation, before LMA insertion was attempted again. Spontaneous breathing was maintained, if possible, during the study period (from the start of anaesthesia to 2 min after LMA insertion). If prolonged apnoea developed (lasting > 30 s), manual ventilation was HJ Kwak, YJ Chae, KC Lee et al.
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performed. After LMA insertion, anaesthesia was maintained with 3% sevoflurane mixed in 100% oxygen, without surgical stimulation.
Time to loss of eyelash reflex, LMA insertion time, episodes of prolonged apnoea (lasting > 30 s) and other adverse events (excitation, cough and extremity movement) during induction were recorded. Haemodynamic variables including heart rate (HR) and mean arterial pressure (MAP) were measured at the following time-points: immediately before anaesthetic induction (T 0 /baseline); and 1 and 2 min after anaesthetic induction (T 1 and T 2 , respectively); immediately before LMA insertion (T 3 ); 1 and 2 min after LMA insertion (T 4 and T 5 , respectively). The primary outcome measure was the proportion of patients who had first-attempt LMA insertion conditions rated as excellent.
STATISTICAL ANALYSES
The sample size required for a statistically significant difference in the proportion of patients with first-attempt LMA insertion conditions rated as excellent was 31 patients in each group (with an α-error of 0.05 and a study power of 80%). This estimate was based on a previous report comparing the proportion of patients with excellent LMA insertion conditions after anaesthesia. 9 The sample size was increased to 34 as the expected drop-out rate was 10%.
All statistical analyses were performed using the SPSS ® software package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Data were reported as number (n) of patients or mean values ± SD. Variables between the groups were compared using one-way analysis of variance with Bonferroni post hoc testing or a χ 2 -test as appropriate. A P-value of < 0.05 was considered to be statistically significant.
Results
A total of 100 patients completed the study (control group n = 33, R1 group n = 34, R2 group n = 33). Two patients were excluded from the final analysis due to lack of patient cooperation and technical problems. There were no between-group differences in patient characteristics, with the exception that the incidence of apnoea episodes was significantly higher in the R2 group than in the control or R1 groups (P < 0.05; Table 1) . A significantly higher proportion of patients had excellent insertion conditions in group R2 compared with the control group (P < 0.05) ( Table 2) . Nine patients were given rocuronium after failure of the second insertion attempt (control group n = 5, R1 group n = 2, R2 group n = 2).
Haemodynamic data for patients with excellent insertion conditions (Table 3) showed significant decreases in HR after LMA insertion in groups R1 and R2, compared with the control group. There were no episodes of bradycardia or hypotension requiring treatment during induction of anaesthesia. No other adverse events of clinical significance (such as oxygen desaturation or truncal [muscle] rigidity), were observed.
Discussion
Coadministration of opioids during sevoflurane inhalation induction has been used to facilitate LMA insertion. 9 Alfentanil has been reported to have a synergistic effect with sevoflurane on suppression of upper airway reflexes, and to reduce excitatory phenomena during sevoflurane induction. 9 Remifentanil has been shown to improve LMA insertion conditions in adults during propofol anaesthesia. 10, 16, 17 Remifentanil TCI significantly improved LMA insertion conditions during sevoflurane induction in the present study. These findings may be HJ Kwak, YJ Chae, KC Lee et al. 18, 19 Manyam et al. 18 demonstrated that the amount of sevoflurane necessary to produce sedation and analgesia was synergistically decreased by remifentanil. Research has also demonstrated that administering a combination of low doses of fentanyl and midazolam prior to sevoflurane inhalation induction provided more rapid and less eventful insertion conditions for the ProSeal™ LMA. 20 Higher concentrations of remifentanil (such as 3 or 4 ng/ml) were not assessed in the present study due to the risks of significant haemodynamic depression or prolonged apnoea episodes. 21, 22 Sevoflurane inhalation induction allows the maintenance of spontaneous ventilation, 23, 24 which is important in patients with potentially difficult airways or in those undergoing surgical procedures of a shortduration. 25 In the R2 group, in the present study, the remifentanil effect-site concentration of 2 ng/ml improved insertion conditions but increased the incidence of apnoea compared with the other treatment groups. A target remifentanil effect-site concentration of 2 ng/ml, used in conjunction with sevoflurane inhalation induction should, therefore, be undertaken with caution when maintenance of spontaneous ventilation is mandatory. The significant decreases in HR observed after LMA insertion (which were observed in the present study among patients receiving remifentanil during anaesthesia compared with patients in the control group) may be associated with bradycardia induced by remifentanil. 26 Differences in HR among the groups may, however, not be of clinical signficance because no episodes of severe bradycardia or hypotension requiring treatment were recorded during the present study.
LMA insertion with sevoflurane and remifentanil TABLE 1: Comparison of the characteristics and induction profiles of adult patients who underwent laryngeal mask airway (LMA) insertion during sevoflurane anaesthesia with targetcontrolled infusions of either normal saline (control group), or remifentanil (target effectsite concentrations of 1 ng/ml [R1 group] or 2 ng/ml [R2 group])
Control
The present study did not utilize a doseresponse design, therefore the 95% effective concentration (EC 95 ) for remifentanil for optimal LMA insertion conditions was not calculated. Further studies are necessary to determine the EC 95 values for remifentanil for coadministration with sevoflurane.
In conclusion, although episodes of apnoea were more frequent when a remifentanil TCI target effect-site concentration of 2 ng/ml was used during sevoflurane induction with tidal volume breathing, compared with normal saline or a target effect-site concentration of 1 ng/ml, the higher remifentanil concentration provided excellent LMA insertion conditions without increasing haemodynamic instability.
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